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Figure 2. Association between anaerobic activity of treatment for peri-
transplant fever during allo BMT hospitalization and subsequent GVHD-
related mortality. Patients treated for peri-transplant fever during allo BMT
hospitalization at MSKCC were treated with antibiotics containing signiﬁcant
activity against obligate anaerobes (piperacillin-tazobactam, ticarcillin-clav-
ulanate, imipenem-cilastatin, meropenem) or with antibiotics without sig-
niﬁcant activity against obligate anaerobes (ceftriaxone, ceftazidime, cefepime,
aztreonam).
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Background: Autologous stem cell transplant (ASCT) is the
standard of care for patients (pts) with relapsed/refractory
Hodgkin lymphoma (HL), providing a cure for approximately
50% of pts; however, most pts with risk factors will progress
post-ASCT (Sureda 2005). Brentuximab vedotin comprises anantieCD30 antibody conjugated by a protease-cleavable
linker to a microtubule-disrupting agent, monomethyl auri-
statin E (MMAE), and has an objective response rate of 75% in
relapsed or refractory HL. The AETHERA trial was initiated to
evaluate whether early treatment with brentuximab vedotin
post-ASCT can prevent progression in pts with HL (Clinical-
Trials.gov #NCT01100502).
Methods: The AETHERA trial is a phase 3, randomized,
double-blind, placebo-controlled, multicenter study. After
ASCT, pts received brentuximab vedotin 1.8 mg/kg q3wk or
placebo for up to 16 cycles. Pts with disease progressionwere
to discontinue therapy and could request unblinding; these
pts may have received subsequent brentuximab vedotin on
another clinical trial or on-label in some regions. The primary
endpoint is progression-free survival (PFS) per an indepen-
dent review facility (IRF).
Results: A total of 329 pts were randomized at 78 sites in the
US and Europe. The median age was 32 years (range, 18e76)
and 53% were male. Pts were enrolled in 1 of 3 high-risk
categories: refractory to frontline (FL) therapy: 196 pts (60%),
relapse <12 mos after FL therapy: 107 pts (33%), and relapse
12 mos after FL therapy with extranodal disease: 26 pts
(8%). Response to salvage therapy pre-ASCT was complete
remission: 137 pts (42%), partial remission: 112 pts (34%),
and stable disease: 80 pts (24%). The median number of prior
systemic therapies was 2 (range, 2e8); 47% of pts received
more than 2 prior systemic therapies. Prior to pre-ASCT
salvage therapy, 106 pts (32%) had extranodal involvement
and 87 pts (26%) had B symptoms. Prior to ASCT,110 pts (33%)
were PETenegative, 116 pts (35%) were PET-positive, and PET
status was unknown for 103 pts (31%). All pts had completed
or discontinued study treatment as of August 2013. The
median number of treatment cycles was 15.
Adverse events (AEs) of any grade in >15% of all pts were
peripheral sensory neuropathy (36%), upper respiratory tract
infection (25%), neutropenia (24%), fatigue (21%), cough
(19%), and pyrexia (17%). Grade 3 or higher AEs in 10 pts
were neutropenia (20%), peripheral sensory neuropathy (6%),
thrombocytopenia (3%), and peripheral motor neuropathy
(3%).
The primary results were released on September 29th,
2014. The PFS per IRF for patients who received brentuximab
vedotin was statistically signiﬁcantly improved compared to
patients who received placebo (hazard ratio 0.57; P¼0.001).
Conclusions: Brentuximab vedotin signiﬁcantly improved
the post-ASCT PFS of patients with HL. Complete efﬁcacy and
safety data will be presented at the conference.5
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Background: Hematopoietic stem cell (HSC) gene therapy
has the potential to induce globin production in the RBC
